3,122 Shares in IQVIA Holdings Inc. (NYSE:IQV) Acquired by Client 1ST Advisory Group LLC

Client 1ST Advisory Group LLC acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 3,122 shares of the medical research company’s stock, valued at approximately $614,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Nordea Investment Management AB increased its position in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares during the period. Simplify Asset Management Inc. grew its position in shares of IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares in the last quarter. Versor Investments LP bought a new position in shares of IQVIA during the third quarter worth approximately $1,328,000. JPMorgan Chase & Co. raised its position in shares of IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after buying an additional 583,396 shares in the last quarter. Finally, CIBC Asset Management Inc grew its position in IQVIA by 3.3% during the third quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company’s stock worth $62,501,000 after buying an additional 8,490 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV stock opened at $197.25 on Monday. The business’s 50-day moving average price is $200.09 and its 200-day moving average price is $221.39. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm has a market capitalization of $35.80 billion, a price-to-earnings ratio of 25.89, a PEG ratio of 2.09 and a beta of 1.48.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on IQV. Morgan Stanley dropped their price objective on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday, November 4th. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Barclays decreased their target price on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Redburn Atlantic assumed coverage on shares of IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 price target for the company. Finally, BTIG Research decreased their price objective on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $255.82.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.